Regulators of homologous recombination repair as novel targets for cancer treatment

Frontiers in Genetics

Volumn 6, Issue MAR, 2015, Pages

  Krajewska, Malgorzata ^a   Fehrmann, Rudolf S N ^a   De Vries, Elisabeth G E ^a   van Vugt, Marcel A T M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cell Cycle; DNA Repair; Genomic instability; PARP inhibitors; Recombination

Indexed keywords

EID: 84923609464     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2015.00096     Document Type: Review

References (159)

1. Adamson, B., Smogorzewska, A., Sigoillot, F. D., King, R. W., and Elledge, S. J. (2012). A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat. Cell Biol. 14, 318-328. doi: 10.1038/ncb2426
2. Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J.,et al. (2012). BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30, 2654-2663. doi: 10.1200/JCO.2011.39.8545
3. Anantha, R. W., Vassin, V. M., and Borowiec, J. A. (2007). Sequential and synergistic modification of human RPA stimulates chromosomal DNA repair. J. Biol. Chem. 282, 35910-35923. doi: 10.1074/jbc.M704645200
4. Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M.,et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245-251. doi: 10.1016/S0140-6736(10)60893-8
5. Aylon, Y., Liefshitz, B., and Kupiec, M. (2004). The CDK regulates repair of double-strand breaks by homologous recombination during the cell cycle. EMBO J. 23, 4868-4875. doi: 10.1038/sj.emboj.7600469
6. Barreto-Andrade, J. C., Efimova, E. V., Mauceri, H. J., Beckett, M. A., Sutton, H. G., Darga, T. E.,et al. (2011). Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol. Cancer Ther. 10, 1185-1193. doi: 10.1158/1535-7163.MCT-11-0061
7. Barton, O., Naumann, S. C., Diemer-Biehs, R., Künzel, J., Steinlage, M., Conrad, S.,et al. (2014). Polo-like kinase 3 regulates CtIP during DNA double-strand break repair in G1. J. Cell Biol. 206, 877-894. doi: 10.1083/jcb.201401146
8. Bauer, P. I., Mendeleyeva, J., Kirsten, E., Comstock, J. A., Hakam, A., Buki, K. G.,et al. (2002). Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease. Biochem. Pharmacol. 63, 455-462. doi: 10.1016/S0006-2952(01)00872-3
9. Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B.,et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578. doi: 10.1056/NEJMoa053422
10. Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H.,et al. (2010). 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17, 688-695. doi: 10.1038/nsmb.1831
11. Branzei, D., and Foiani, M. (2008). Regulation of DNA repair throughout the cell cycle. Nat. Rev. Mol. Cell Biol. 9, 297-308. doi: 10.1038/nrm2351
12. Bryant, H. E., Petermann, E., Schultz, N., Jemth, A.-S., Loseva, O., Issaeva, N.,et al. (2009). PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 28, 2601-2615. doi: 10.1038/emboj.2009.206
13. Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E.,et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917. doi: 10.1038/nature03443
14. Budke, B., Logan, H. L., Kalin, J. H., Zelivianskaia, A. S., Cameron McGuire, W., Miller, L. L.,et al. (2012). RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res. 40, 7347-7357. doi: 10.1093/nar/gks353
15. Buis, J., Stoneham, T., Spehalski, E., and Ferguson, D. O. (2012). Mre11 regulates CtIP-dependent double-strand break repair by interaction with CDK2. Nat. Struct. Mol. Biol. 19, 246-252. doi: 10.1038/nsmb.2212
16. Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M.,et al. (2008). Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res. Treat. 108, 289-296. doi: 10.1007/s10549-007-9600-1
17. Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M.,et al. (2010). Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol. 28, 375-379. doi: 10.1200/JCO.2008.20.7019
18. Caldecott, K. W. (2008). Single-strand break repair and genetic disease. Nat. Rev. Genet. 9, 619-631. doi: 10.1038/nrg2380
19. Callen, E., Di Virgilio, M., Kruhlak, M. J., Nieto-Soler, M., Wong, N., Chen, H.-T.,et al. (2013). 53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions. Cell 153, 1266-1280. doi: 10.1016/j.cell.2013.05.023
20. Cancer Genome Atlas Research Network. (2011). Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615. doi: 10.1038/nature10166
21. Chaouki, A. S., and Salz, H. K. (2006). Drosophila SPF45: a bifunctional protein with roles in both splicing and DNA repair. PLoS genet. 2:e178. doi: 10.1371/journal.pgen.0020178
22. Chapman, J. R., Taylor, M. R. G., and Boulton, S. J. (2012). Playing the end game: DNA double-strand break repair pathway choice. Mol. Cell 47, 497-510. doi: 10.1016/j.molcel.2012.07.029
23. Chen, G., Yuan, S. S., Liu, W., Xu, Y., Trujillo, K., Song, B.,et al. (1999). Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J. Biol. Chem. 274, 12748-12752. doi: 10.1074/jbc.274.18. 12748
24. Chen, L., Nievera, C. J., Lee, A. Y.-L., and Wu, X. (2008). Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J. Biol. Chem. 283, 7713-7720. doi: 10.1074/jbc.M710245200
25. Choi, S., Gamper, A. M., White, J. S., and Bakkenist, C. J. (2010). Inhibition of ATM kinase activity does not phenocopy ATM protein disruption: implications for the clinical utility of ATM kinase inhibitors. Cell Cycle 9, 4052-4057.
26. Ciccia, A., and Elledge, S. J. (2010). The DNA damage response: making it safe to play with knives. Mol. Cell 40, 179-204. doi: 10.1016/j.molcel.2010.09.019
27. Clague, J., Wilhoite, G., Adamson, A., Bailis, A., Weitzel, J. N., and Neuhausen, S. L. (2011). RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. PLoS ONE 6:e25632. doi: 10.1371/journal.pone.0025632
28. Cortez, D., Wang, Y., Qin, J., and Elledge, S. J. (1999). Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286, 1162-1166. doi: 10.1126/science.286.5442.1162
29. Cron, K. R., Zhu, K., Kushwaha, D. S., Hsieh, G., Merzon, D., Rameseder, J.,et al. (2013). Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. PLoS ONE 8:e73710. doi: 10.1371/journal.pone.0073710
30. Davidson, D., Wang, Y., Aloyz, R., and Panasci, L. (2013). The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Invest. New Drugs 31, 461-468. doi: 10.1007/s10637-012-9886-7
31. Dewey, W. C., Sapareto, S. A., and Betten, D. A. (1978). Hyperthermic radiosen-sitization of synchronous Chinese hamster cells: relationship between lethality and chromosomal aberrations. Radiat. Res. 76, 48-59. doi: 10.2307/3574926
32. Di Virgilio, M., Callen, E., Yamane, A., Zhang, W., Jankovic, M., Gitlin, A. D.,et al. (2013). Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching. Science 339, 711-715. doi: 10.1126/science.1230624
33. Dungey, F. A., Caldecott, K. W., and Chalmers, A. J. (2009). Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol. Cancer Ther. 8, 2243-2254. doi: 10.1158/1535-7163.MCT-09-0201
34. Dutertre, S., Sekhri, R., Tintignac, L. A., Onclercq-Delic, R., Chatton, B., Jaulin, C.,et al. (2002). Dephosphorylation and subcellular compartment change of the mitotic Bloom's syndrome DNA helicase in response to ionizing radiation. J. Biol. Chem. 277, 6280-6286. doi: 10.1074/jbc.M105735200
35. Elledge, S. J., and Amon, A. (2002). The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. Cancer Cell 1, 129-132. doi: 10.1016/S1535-6108(02)00041-7
36. Eppink, B., Krawczyk, P. M., Stap, J., and Kanaar, R. (2012). Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. Int. J. Hyperthermia 28, 509-517. doi: 10.3109/02656736.2012.695427
37. Esashi, F., Christ, N., Gannon, J., Liu, Y., Hunt, T., Jasin, M.,et al. (2005). CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434, 598-604. doi: 10.1038/nature03404
38. Escribano-Díaz, C., Orthwein, A., Fradet-Turcotte, A., Xing, M., Young, J. T. F., Tkác, J.,et al. (2013). A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol. Cell. 49, 872-883. doi: 10.1016/j.molcel.2013.01.001
39. Esteller, M., Silva, J. M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E.,et al. (2000). Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92, 564-569. doi: 10.1093/jnci/92.7.564
40. Falck, J., Forment, J. V., Coates, J., Mistrik, M., Lukas, J., Bartek, J.,et al. (2012). CDK targeting of NBS1 promotes DNA-end resection, replication restart and homologous recombination. EMBO Rep. 13, 561-568. doi: 10.1038/embor.2012.58
41. Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B.,et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921. doi: 10.1038/nature03445
42. Feng, L., Fong, K.-W., Wang, J., Wang, W., and Chen, J. (2013). RIF1 counteracts BRCA1-mediated end resection during DNA repair. J. Biol. Chem. 288, 11135-11143. doi: 10.1074/jbc.M113.457440
43. Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M.,et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134. doi: 10.1056/NEJMoa0900212
44. Francia, S., Michelini, F., Saxena, A., Tang, D., de Hoon, M., Anelli, V.,et al. (2012). Site-specific DICER and DROSHA RNA products control the DNA-damage response. Nature 488, 231-235. doi: 10.1038/nature11179
45. Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S.,et al. (1994). BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120-122. doi: 10.1126/science.7939630
46. Gatei, M., Jakob, B., Chen, P., Kijas, A. W., Becherel, O. J., Gueven, N.,et al. (2011). ATM protein-dependent phosphorylation of Rad50 protein regulates DNA repair and cell cycle control. J. Biol. Chem. 286, 31542-31556. doi: 10.1074/jbc.M111.258152
47. Gatei, M., Young, D., Cerosaletti, K. M., Desai-Mehta, A., Spring, K., Kozlov, S.,et al. (2000). ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat. Genet. 25, 115-119. doi: 10.1038/75508
48. Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K.,et al. (2011). Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852-861. doi: 10.1016/S1470-2045(11)70214-5
49. Golding, S. E., Morgan, R. N., Adams, B. R., Hawkins, A. J., Povirk, L. F., and Valerie, K. (2009). Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol. Ther. 8, 730-738. doi: 10.4161/cbt.8.8.7927
50. Gowen, L. C., Johnson, B. L., Latour, A. M., Sulik, K. K., and Koller, B. H. (1996). Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet. 12, 191-194. doi: 10.1038/ng0296-191
51. Hakem, R., de la Pompa, J. L., Sirard, C., Mo, R., Woo, M., Hakem, A.,et al. (1996). The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009-1023. doi: 10.1016/S0092-8674(00)81302-1
52. Hershko, A., and Ciechanover, A. (1998). The ubiquitin system. Annu. Rev. Biochem. 67, 425-479. doi: 10.1146/annurev.biochem.67.1.425
53. Huang, S. M., and Harari, P. M. (2000). Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6, 2166-2174.
54. Huertas, P., Cortés-Ledesma, F., Sartori, A. A., Aguilera, A., and Jackson, S. P. (2008). CDK targets Sae2 to control DNA-end resection and homologous recombination. Nature 455, 689-692. doi: 10.1038/nature07215
55. Huertas, P., and Jackson, S. P. (2009). Human CtIP mediates cell cycle control of DNA end resection and double strand break repair. J. Biol. Chem. 284, 9558-9565. doi: 10.1074/jbc.M808906200
56. Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A.,et al. (2012). PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2, 1036-1047. doi: 10.1158/2159-8290.CD-11-0348
57. Ira, G., Pellicioli, A., Balijja, A., Wang, X., Fiorani, S., Carotenuto, W.,et al. (2004). DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1. Nature 431, 1011-1017. doi: 10.1038/nature02964
58. Jackson, S. P., and Bartek, J. (2009). The DNA-damage response in human biology and disease. Nature 461, 1071-1078. doi: 10.1038/nature08467
59. Jackson, S. P., and Durocher, D. (2013). Regulation of DNA damage responses by ubiquitin and SUMO. Mol. Cell 49, 795-807. doi: 10.1016/j.molcel.2013.01.017
60. Jacquemont, C., and Taniguchi, T. (2007). Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res. 67, 7395-7405. doi: 10.1158/0008-5472.CAN-07-1015
61. Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C. M., Lukas, J.,et al. (2006). ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8, 37-45. doi: 10.1038/ncb1337
62. Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, F.,et al. (2011). A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 474, 230-234. doi: 10.1038/nature10155
63. Johnson, N., Li, Y.-C., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J.,et al. (2011). Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat. Med. 17, 875-882. doi: 10.1038/nm.2377
64. Johnson, R. D., and Jasin, M. (2000). Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J. 19, 3398-3407. doi: 10.1093/emboj/19.13.3398
65. Kampinga, H. H., Dynlacht, J. R., and Dikomey, E. (2004). Mechanism of radiosensitization by hyperthermia (>or = 43 degrees C) as derived from studies with DNA repair defective mutant cell lines. Int. J. Hyperthermia 20, 131-139. doi: 10.1080/02656730310001627713
66. Kass, E. M., Helgadottir, H. R., Chen, C.-C., Barbera, M., Wang, R., Westermark, U. K.,et al. (2013). Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase. Proc. Natl. Acad. Sci. U.S.A. 110, 5564-5569. doi: 10.1073/pnas.1216824110
67. Kim, J. H., Hahn, E. W., and Tokita, N. (1978). Combination hyperthermia and radiation therapy for cutaneous malignant melanoma. Cancer 41, 2143-2148.
68. Knight, L. A., Di Nicolantonio, F., Whitehouse, P., Mercer, S., Sharma, S., Glaysher, S.,et al. (2004). The in vitro effect of gefitinib ("Iressa") alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 4:83. doi: 10.1186/1471-2407-4-83
69. Köcher, S., Rieckmann, T., Rohaly, G., Mansour, W. Y., Dikomey, E., Dornreiter, I.,et al. (2012). Radiation-induced double-strand breaks require ATM but not Artemis for homologous recombination during S-phase. Nucleic Acids Res. 40, 8336-8347. doi: 10.1093/nar/gks604
70. Kozlov, S. V., Graham, M. E., Jakob, B., Tobias, F., Kijas, A. W., Tanuji, M.,et al. (2011). Autophosphorylation and ATM activation: additional sites add to the complexity. J. Biol. Chem. 286, 9107-9119. doi: 10.1074/jbc.M110. 204065
71. Krajewska, M., Heijink, A. M., Bisselink, Y. J. W. M., Seinstra, R. I., Silljé, H. H. W., de Vries, E. G. E.,et al. (2013). Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene 32, 3001-3008. doi: 10.1038/onc.2012.296
72. Krawczyk, P. M., Eppink, B., Essers, J., Stap, J., Rodermond, H., Odijk, H.,et al. (2011). Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc. Natl. Acad. Sci. U.S.A. 108, 9851-9856. doi: 10.1073/pnas.1101053108
73. Krejci, L., Altmannova, V., Spirek, M., and Zhao, X. (2012). Homologous recombination and its regulation. Nucleic Acids Res. 40, 5795-5818. doi: 10.1093/nar/gks270
74. Lafranchi, L., de Boer, H. R., de Vries, E. G. E., Ong, S.-E., Sartori, A. A., and van Vugt, M. A. T. M. (2014). APC/C(Cdh1) controls CtIP stability during the cell cycle and in response to DNA damage. EMBO J. 33, 2860-2879. doi: 10.15252/embj.201489017
75. Lancaster, J. M., Wooster, R., Mangion, J., Phelan, C. M., Cochran, C., Gumbs, C.,et al. (1996). BRCA2 mutations in primary breast and ovarian cancers. Nat. Genet. 13, 238-240. doi: 10.1038/ng0696-238
76. Lee, J.-H., and Paull, T. T. (2007). Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26, 7741-7748. doi: 10.1038/sj.onc.1210872
77. Li, L., Wang, H., Yang, E. S., Arteaga, C. L., and Xia, F. (2008). Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 68, 9141-9146. doi: 10.1158/0008-5472.CAN-08-1127
78. Li, S., Ting, N. S., Zheng, L., Chen, P. L., Ziv, Y., Shiloh, Y.,et al. (2000). Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 406, 210-215. doi: 10.1038/35018134
79. Li, X., and Heyer, W.-D. (2008). Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 18, 99-113. doi: 10.1038/cr.2008.1
80. Liccardi, G., Hartley, J. A., and Hochhauser, D. (2011). EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 71, 1103-1114. doi: 10.1158/0008-5472.CAN-10-2384
81. Lieber, M. R. (2010). The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 79, 181-211. doi: 10.1146/annurev.biochem.052308.093131
82. Lim, D. S., and Hasty, P. (1996). A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol. Cell. Biol. 16, 7133-7143.
83. Lim, D. S., Kim, S. T., Xu, B., Maser, R. S., Lin, J., Petrini, J. H.,et al. (2000). ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404, 613-617. doi: 10.1038/35007091
84. Limbo, O., Chahwan, C., Yamada, Y., de Bruin, R. A. M., Wittenberg, C., and Russell, P. (2007). Ctp1 is a cell-cycle-regulated protein that functions with Mre11 complex to control double-strand break repair by homologous recombination. Mol. Cell 28, 134-146. doi: 10.1016/j.molcel.2007.09. 009
85. Lin, H.-R., Ting, N. S. Y., Qin, J., and Lee, W.-H. (2003). M phase-specific phosphorylation of BRCA2 by Polo-like kinase 1 correlates with the dissociation of the BRCA2-P/CAF complex. J. Biol. Chem. 278, 35979-35987. doi: 10.1074/jbc.M210659200
86. Linding, R., Jensen, L. J., Ostheimer, G. J., van Vugt, M. A. T. M., Jørgensen, C., Miron, I. M.,et al. (2007). Systematic discovery of in vivo phosphorylation networks. Cell 129, 1415-1426. doi: 10.1016/j.cell.2007.05.052
87. Lindquist, S., and Craig, E. A. (1988). The heat-shock proteins. Annu. Rev. Genet. 22, 631-677. doi: 10.1146/annurev.ge.22.120188.003215
88. Loveday, C., Turnbull, C., Ruark, E., Xicola, R. M. M., Ramsay, E., Hughes, D.,et al. (2012). Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat. Genet. 44, 475-476. doi: 10.1038/ng.2224
89. Ludwig, T., Chapman, D. L., Papaioannou, V. E., and Efstratiadis, A. (1997). Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 11, 1226-1241. doi: 10.1101/gad.11.10.1226
90. Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J.,et al. (2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-1166. doi: 10.1126/science.1140321
91. McKinney, J. S., Sethi, S., Tripp, J. D., Nguyen, T. N., Sanderson, B. A., Westmoreland, J. W.,et al. (2013). A multistep genomic screen identifies new genes required for repair of DNA double-strand breaks in Saccharomyces cerevisiae. BMC Genomics 14:251. doi: 10.1186/1471-2164-14-251
92. Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q.,et al. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024. doi: 10.1056/NEJMoa051918
93. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S.,et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71. doi: 10.1126/science.7545954
94. Min, A., Im, S.-A., Yoon, Y.-K., Song, S.-H., Nam, H.-J., Hur, H.-S.,et al. (2013). RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. Mol. Cancer Ther. 12, 865-877. doi: 10.1158/1535-7163.MCT-12-0950
95. Montecucco, A., and Biamonti, G. (2013). Pre-mRNA processing factors meet the DNA damage response. Front. Genet. 4:102. doi: 10.3389/fgene.2013.00102
96. Morgan, D. O. (1997). Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13, 261-291. doi: 10.1146/annurev.cellbio.13.1.261
97. Morrison, C., Sonoda, E., Takao, N., Shinohara, A., Yamamoto, K., and Takeda, S. (2000). The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J. 19, 463-471. doi: 10.1093/emboj/19.3.463
98. Moyer, J. D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunningham, A.,et al. (1997). Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57, 4838-4848.
99. Mukherjee, B., McEllin, B., Camacho, C. V., Tomimatsu, N., Sirasanagandala, S., Nannepaga, S.,et al. (2009). EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res. 69, 4252-4259. doi: 10.1158/0008-5472.CAN-08-4853
100. Müller-Tidow, C., Ji, P., Diederichs, S., Potratz, J., Bäumer, N., Köhler, G.,et al. (2004). The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol. Cell. Biol. 24, 8917-8928. doi: 10.1128/MCB.24.20.8917-8928. 2004
101. Murakawa, Y., Sonoda, E., Barber, L. J., Zeng, W., Yokomori, K., Kimura, H.,et al. (2007). Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res. 67, 8536-8543. doi: 10.1158/0008-5472.CAN-07-1166
102. Murga, M., Campaner, S., López-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F.,et al. (2011). Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol. 18, 1331-1335. doi: 10.1038/nsmb.2189
103. Myllynen, L., Rieckmann, T., Dahm-Daphi, J., Kasten-Pisula, U., Petersen, C., Dikomey, E.,et al. (2011). In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status. Radiother. Oncol. 101, 147-151. doi: 10.1016/j.radonc.2011.05.046
104. Neri, P., Ren, L., Gratton, K., Stebner, E., Johnson, J., Klimowicz, A.,et al. (2011). Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood 118, 6368-6379. doi: 10.1182/blood-2011-06-363911
105. Noguchi, M., Yu, D., Hirayama, R., Ninomiya, Y., Sekine, E., Kubota, N.,et al. (2006). Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem. Biophys. Res. Commun. 351, 658-663. doi: 10.1016/j.bbrc.2006.10.094
106. Nowsheen, S., Cooper, T., Stanley, J. A., and Yang, E. S. (2012). Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS ONE 7:e46614. doi: 10.1371/journal.pone.0046614
107. Overgaard, J., González González, D., Hulshof, M. C., Arcangeli, G., Dahl, O., Mella, O.,et al. (1995). Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European society for hyperthermic oncology. Lancet 345, 540-543. doi: 10.1016/S0140-6736(95)90463-8
108. Pajonk, F., Pajonk, K., and McBride, W. H. (2000). Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int. J. Radiat. Oncol. Biol. Phys. 47, 1025-1032. doi: 10.1016/S0360-3016(00)00516-2
109. Petermann, E., Orta, M. L., Issaeva, N., Schultz, N., and Helleday, T. (2010). Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol. Cell 37, 492-502. doi: 10.1016/j.molcel.2010.01.021
110. Peterson, S. E., Li, Y., Wu-Baer, F., Chait, B. T., Baer, R., Yan, H.,et al. (2013). Activation of DSB processing requires phosphorylation of CtIP by ATR. Mol. Cell 49, 657-667. doi: 10.1016/j.molcel.2012.11.020
111. Pierce, A. J., Johnson, R. D., Thompson, L. H., and Jasin, M. (1999). XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13, 2633-2638. doi: 10.1101/gad.13.20.2633
112. Prevo, R., Fokas, E., Reaper, P. M., Charlton, P. A., Pollard, J. R., McKenna, W. G.,et al. (2012). The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol. Ther. 13, 1072-1081. doi: 10.4161/cbt.21093
113. Quatrale, A. E., Porcelli, L., Silvestris, N., Colucci, G., Angelo, A., and Azzariti, A. (2011). EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front. Biosci. (Landmark Ed.) 16:1962-1972. doi: 10.2741/3833
114. Quiros, S., Roos, W. P., and Kaina, B. (2011). Rad51 and BRCA2-New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS ONE 6:e27183. doi: 10.1371/journal.pone.0027183
115. Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A.,et al. (2007). PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39, 165-167. doi: 10.1038/ng1959
116. Rice, J. C., Ozcelik, H., Maxeiner, P., Andrulis, I., and Futscher, B. W. (2000). Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21, 1761-1765. doi: 10.1093/carcin/21.9.1761
117. Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C.,et al. (2008). Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120. doi: 10.1038/nature06633
118. San Filippo, J., Sung, P., and Klein, H. (2008). Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 77, 229-257. doi: 10.1146/annurev.biochem.77.061306.125255
119. Sartori, A. A., Lukas, C., Coates, J., Mistrik, M., Fu, S., Bartek, J.,et al. (2007). Human CtIP promotes DNA end resection. Nature 450, 509-514. doi: 10.1038/nature06337
120. Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., and Jasin, M. (2011). Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 145, 529-542. doi: 10.1016/j.cell.2011.03.041
121. Sebastian de Bono, J., Sandhu, S., and Attard, G. (2011). Beyond hormone therapy for prostate cancer with PARP inhibitors. Cancer Cell 19, 573-574. doi: 10.1016/j.ccr.2011.05.003
122. Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D. S., Regel, E., Dinh, C.,et al. (1997). Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386, 804-810. doi: 10.1038/386804a0
123. Sharma, S. V., Bell, D. W., Settleman, J., and Haber, D. A. (2007). Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181. doi: 10.1038/nrc2088
124. Slabicki, M., Theis, M., Krastev, D. B., Samsonov, S., Mundwiller, E., Junqueira, M.,et al. (2010). A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PLoS Biol. 8:e1000408. doi: 10.1371/journal.pbio.1000408
125. Sleeth, K. M., Sørensen, C. S., Issaeva, N., Dziegielewski, J., Bartek, J., and Helleday, T. (2007). RPA mediates recombination repair during replication stress and is displaced from DNA by checkpoint signalling in human cells. J. Mol. Biol. 373, 38-47. doi: 10.1016/j.jmb.2007.07.068
126. Smolka, M. B., Albuquerque, C. P., Chen, S.-H., and Zhou, H. (2007). Proteome-wide identification of in vivo targets of DNA damage checkpoint kinases. Proc. Natl. Acad. Sci. U.S.A. 104, 10364-10369. doi: 10.1073/pnas.0701622104
127. Sneed, P. K., Stauffer, P. R., McDermott, M. W., Diederich, C. J., Lamborn, K. R., Prados, M. D.,et al. (1998). Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 40, 287-295. doi: 10.1016/S0360-3016(97)00731-1
128. Sørensen, C. S., Hansen, L. T., Dziegielewski, J., Syljuåsen, R. G., Lundin, C., Bartek, J.,et al. (2005). The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. 7, 195-201. doi: 10.1038/ncb1212
129. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A.,et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550. doi: 10.1073/pnas.0506580102
130. Suzuki, A., de la Pompa, J. L., Hakem, R., Elia, A., Yoshida, R., Mo, R.,et al. (1997). Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev. 11, 1242-1252. doi: 10.1101/gad.11.10.1242
131. Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., and Taniguchi, T. (2008). Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581-2586. doi: 10.1158/0008-5472.CAN-08-0088
132. Symington, L. S., and Gautier, J. (2011). Double-strand break end resection and repair pathway choice. Annu. Rev. Genet. 45, 247-271. doi: 10.1146/annurev-genet-110410-132435
133. Tan, D. S. P., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S.,et al. (2008). "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol. 26, 5530-5536. doi: 10.1200/JCO.2008.16.1703
134. Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H.,et al. (2003). Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9, 568-574. doi: 10.1038/nm852
135. Trenz, K., Smith, E., Smith, S., and Costanzo, V. (2006). ATM and ATR promote Mre11 dependent restart of collapsed replication forks and prevent accumulation of DNA breaks. EMBO J. 25, 1764-1774. doi: 10.1038/sj.emboj.7601045
136. Trojanek, J., Ho, T., Del Valle, L., Nowicki, M., Wang, J. Y., Lassak, A.,et al. (2003). Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol. Cell. Biol. 23, 7510-7524. doi: 10.1128/MCB.23.21.7510-7524.2003
137. Turner, N. C., Lord, C. J., Iorns, E., Brough, R., Swift, S., Elliott, R.,et al. (2008). A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27, 1368-1377. doi: 10.1038/emboj.2008.61
138. Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D.,et al. (2007). BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26, 2126-2132. doi: 10.1038/sj.onc.1210014
139. Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N.,et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244. doi: 10.1016/S0140-6736(10)60892-6
140. Urbanska, K., Pannizzo, P., Lassak, A., Gualco, E., Surmacz, E., Croul, S.,et al. (2009). Estrogen receptor beta-mediated nuclear interaction between IRS-1 and Rad51 inhibits homologous recombination directed DNA repair in medulloblastoma. J. Cell. Physiol. 219, 392-401. doi: 10.1002/jcp.21683
141. van der Zee, J., González González, D., van Rhoon, G. C., van Dijk, J. D., van Putten, W. L., and Hart, A. A. (2000). Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch deep hyperthermia group. Lancet 355, 1119-1125. doi: 10.1016/S0140-6736(00)02059-6
142. van Vugt, M. A. T. M., and Medema, R. H. (2005). Getting in and out of mitosis with Polo-like kinase-1. Oncogene 24, 2844-2859. doi: 10.1038/sj.onc.1208617
143. Vaziri, S. A. J., Hill, J., Chikamori, K., Grabowski, D. R., Takigawa, N., Chawla-Sarkar, M.,et al. (2005). Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin. Mol. Cancer Ther. 4, 1880-1890. doi: 10.1158/1535-7163.MCT-05-0222
144. Vernon, C. C., Hand, J. W., Field, S. B., Machin, D., Whaley, J. B., van der Zee, J.,et al. (1996). Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International collaborative hyperthermia group. Int. J. Radiat. Oncol. Biol. Phys. 35, 731-744. doi: 10.1016/0360-3016(96)00154-X
145. Vollebergh, M. A., Lips, E. H., Nederlof, P. M., Wessels, L. F. A., Schmidt, M. K., van Beers, E. H.,et al. (2011). An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann. Oncol. 22, 1561-1570. doi: 10.1093/annonc/mdq624
146. Wang, H., Shi, L. Z., Wong, C. C. L., Han, X., Hwang, P. Y.-H., Truong, L. N.,et al. (2013). The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR-mediated double-strand break repair. PLoS genet. 9:e1003277. doi: 10.1371/journal.pgen.1003277
147. Willers, H., Taghian, A. G., Luo, C.-M., Treszezamsky, A., Sgroi, D. C., and Powell, S. N. (2009). Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol. Cancer Res. 7, 1304-1309. doi: 10.1158/1541-7786.MCR-09-0149
148. Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N.,et al. (1994). Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265, 2088-2090. doi: 10.1126/science.8091231
149. Wyman, C., Ristic, D., and Kanaar, R. (2004). Homologous recombination-mediated double-strand break repair. DNA Repair 3, 827-833. doi: 10.1016/j.dnarep.2004.03.037
150. Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X. W.,et al. (1999). Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3, 389-395. doi: 10.1016/S1097-2765(00)80466-9
151. Yata, K., Lloyd, J., Maslen, S., Bleuyard, J.-Y., Skehel, M., Smerdon, S. J.,et al. (2012). Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair. Mol. Cell 45, 371-383. doi: 10.1016/j.molcel.2011.12.028
152. Yu, X., and Chen, J. (2004). DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol. Cell. Biol. 24, 9478-9486. doi: 10.1128/MCB.24.21.9478-9486.2004
153. Yuan, S. S. F., Chang, H. L., Hou, M. F., Chan, T. F., Kao, Y. H., Wu, Y. C.,et al. (2002). Neocarzinostatin induces Mre11 phosphorylation and focus formation through an ATM- and NBS1-dependent mechanism. Toxicology 177, 123-130. doi: 10.1016/S0300-483X(02)00220-2
154. Zaidi, S., McLaughlin, M., Bhide, S. A., Eccles, S. A., Workman, P., Nutting, C. M.,et al. (2012). The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS ONE 7:e35436. doi: 10.1371/journal.pone.0035436
155. Zhang, J., Willers, H., Feng, Z., Ghosh, J. C., Kim, S., Weaver, D. T.,et al. (2004). Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol. Cell. Biol. 24, 708-718. doi: 10.1128/MCB.24.2.708-718.2004
156. Zhang, N., Kaur, R., Lu, X., Shen, X., Li, L., and Legerski, R. J. (2005). The Pso4 mRNA splicing and DNA repair complex interacts with WRN for processing of DNA interstrand cross-links. J. Biol. Chem. 280, 40559-40567. doi: 10.1074/jbc.M508453200
157. Zhao, S., Weng, Y. C., Yuan, S. S., Lin, Y. T., Hsu, H. C., Lin, S. C.,et al. (2000). Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature 405, 473-477. doi: 10.1038/35013083
158. Zimmermann, M., Lottersberger, F., Buonomo, S. B., Sfeir, A., and de Lange, T. (2013). 53BP1 regulates DSB repair using Rif1 to control 5' end resection. Science 339, 700-704. doi: 10.1126/science.1231573
159. Zou, L., and Elledge, S. J. (2003). Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300, 1542-1548. doi: 10.1126/science.1083430